Recently, a phase I/II trial combining IDO inhibitor (indoximod) and chemotherapy in patients with metastatic pancreatic cancer was completed (NCT02077881), while another phase II clinical study employing another IDO inhibitor (epacadostat) and immunotherapy or cyclophosphamide in pancreatic cancer patients is recruiting (NCT03006302). This evidence concerns the gene IDO1 and pancreatic neoplasm.